• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ETS 转录因子 ELF3（ESE-1）是良性和恶性前列腺中的细胞周期调节剂。

ETS transcription factor ELF3 (ESE-1) is a cell cycle regulator in benign and malignant prostate.

机构信息

Cancer Research Unit, Department of Biology, University of York, Heslington, UK.

Experimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, UK.

出版信息

FEBS Open Bio. 2022 Jul;12(7):1365-1387. doi: 10.1002/2211-5463.13417. Epub 2022 May 6.

DOI:10.1002/2211-5463.13417
PMID:35472129
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9249341/
Abstract

This study aimed to elucidate the role of ELF3, an ETS family member in normal prostate growth and prostate cancer. Silencing ELF3 in both benign prostate (BPH-1) and prostate cancer (PC3) cell lines resulted in decreased colony-forming ability, inhibition of cell migration and reduced cell viability due to cell cycle arrest, establishing ELF3 as a cell cycle regulator. Increased ELF3 expression in more advanced prostate tumours was shown by immunostaining of tissue microarrays and from analysis of gene expression and genetic alteration studies. This study indicates that ELF3 functions not only as a part of normal prostate epithelial growth but also as a potential oncogene in advanced prostate cancers.

摘要

本研究旨在阐明 ELF3（ETS 家族成员之一）在正常前列腺生长和前列腺癌中的作用。沉默良性前列腺（BPH-1）和前列腺癌细胞系（PC3）中的 ELF3 会导致集落形成能力下降、细胞迁移抑制以及细胞活力因细胞周期停滞而降低，从而确立 ELF3 作为细胞周期调节剂的作用。通过组织微阵列的免疫染色以及基因表达和遗传改变研究的分析，显示在更晚期的前列腺肿瘤中 ELF3 表达增加。这项研究表明，ELF3 不仅作为正常前列腺上皮生长的一部分发挥作用，而且在晚期前列腺癌中作为潜在的致癌基因发挥作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/678e/9249341/3ac0154399c5/FEB4-12-1365-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/678e/9249341/263357062c13/FEB4-12-1365-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/678e/9249341/7c5025dff17c/FEB4-12-1365-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/678e/9249341/6f2410d51761/FEB4-12-1365-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/678e/9249341/b2a0aa77cc3f/FEB4-12-1365-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/678e/9249341/10ddaaa5bd5c/FEB4-12-1365-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/678e/9249341/86adb9707aa1/FEB4-12-1365-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/678e/9249341/bbde82cdd37f/FEB4-12-1365-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/678e/9249341/3ac0154399c5/FEB4-12-1365-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/678e/9249341/263357062c13/FEB4-12-1365-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/678e/9249341/7c5025dff17c/FEB4-12-1365-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/678e/9249341/6f2410d51761/FEB4-12-1365-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/678e/9249341/b2a0aa77cc3f/FEB4-12-1365-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/678e/9249341/10ddaaa5bd5c/FEB4-12-1365-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/678e/9249341/86adb9707aa1/FEB4-12-1365-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/678e/9249341/bbde82cdd37f/FEB4-12-1365-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/678e/9249341/3ac0154399c5/FEB4-12-1365-g008.jpg

相似文献

1
ETS transcription factor ELF3 (ESE-1) is a cell cycle regulator in benign and malignant prostate.ETS 转录因子 ELF3（ESE-1）是良性和恶性前列腺中的细胞周期调节剂。
FEBS Open Bio. 2022 Jul;12(7):1365-1387. doi: 10.1002/2211-5463.13417. Epub 2022 May 6.
2
ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-κB and drives prostate cancer progression.ETS 转录因子 ESE1/ELF3 调控一个正反馈回路，该回路持续激活 NF-κB 并驱动前列腺癌进展。
Cancer Res. 2013 Jul 15;73(14):4533-47. doi: 10.1158/0008-5472.CAN-12-4537. Epub 2013 May 16.
3
E74 like ETS transcription factor 3 (ELF3) is a negative regulator of epithelial- mesenchymal transition in bladder carcinoma.E74 样转录因子 3（ELF3）是膀胱癌上皮-间充质转化的负调控因子。
Cancer Biomark. 2019;25(2):223-232. doi: 10.3233/CBM-190013.
4
E26 transformation (ETS)‑specific related transcription factor‑3 (ELF3) orchestrates a positive feedback loop that constitutively activates the MAPK/Erk pathway to drive thyroid cancer.E26 转化（ETS）特异性相关转录因子 3（ELF3）协调一个正反馈回路，该回路持续激活 MAPK/Erk 通路以驱动甲状腺癌。
Oncol Rep. 2019 Jan;41(1):570-578. doi: 10.3892/or.2018.6807. Epub 2018 Oct 18.
5
ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer.ETS 转录因子控制前列腺癌细胞中 EZH2 的转录和肿瘤抑制基因 Nkx3.1 的表观遗传沉默。
PLoS One. 2010 May 10;5(5):e10547. doi: 10.1371/journal.pone.0010547.
6
ELF3, ELF5, EHF and SPDEF Transcription Factors in Tissue Homeostasis and Cancer.ELF3、ELF5、EHF 和 SPDEF 转录因子在组织稳态和癌症中的作用。
Molecules. 2018 Aug 30;23(9):2191. doi: 10.3390/molecules23092191.
7
A transcriptional repressive role for epithelial-specific ETS factor ELF3 on oestrogen receptor alpha in breast cancer cells.上皮特异性ETS因子ELF3在乳腺癌细胞中对雌激素受体α的转录抑制作用。
Biochem J. 2016 Apr 15;473(8):1047-61. doi: 10.1042/BCJ20160019. Epub 2016 Feb 26.
8
ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells.ELF3是卵巢癌细胞上皮-间质转化的负调控因子。
Oncotarget. 2017 Mar 7;8(10):16951-16963. doi: 10.18632/oncotarget.15208.
9
E74-Like Factor 3 Is a Key Regulator of Epithelial Integrity and Immune Response Genes in Biliary Tract Cancer.E74 样因子 3 是胆管癌中上皮完整性和免疫反应基因的关键调节因子。
Cancer Res. 2021 Jan 15;81(2):489-500. doi: 10.1158/0008-5472.CAN-19-2988. Epub 2020 Dec 8.
10
ELF3 promotes epithelial-mesenchymal transition by protecting ZEB1 from miR-141-3p-mediated silencing in hepatocellular carcinoma.ELF3 通过保护 ZEB1 免受 miR-141-3p 介导的沉默来促进肝癌中的上皮-间充质转化。
Cell Death Dis. 2018 Mar 9;9(3):387. doi: 10.1038/s41419-018-0399-y.

引用本文的文献

1
TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanisms.三阴性乳腺癌对紫杉醇的反应模拟了干扰素反应，揭示了细胞周期相关的耐药机制。
Sci Rep. 2025 Feb 4;15(1):4294. doi: 10.1038/s41598-024-82218-9.
2
ELF3 Overexpression Contributes to the Malignant Transformation of HPV16 E6/E7-Immortalized Keratinocytes by Promoting CCNE2 Expression.ELF3过表达通过促进CCNE2表达促进HPV16 E6/E7永生化角质形成细胞的恶性转化。
J Microbiol Biotechnol. 2024 Dec 28;34(12):2484-2491. doi: 10.4014/jmb.2408.08041. Epub 2024 Oct 30.
3
TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanisms.

本文引用的文献

1
FOXM1-Dependent Transcriptional Regulation of EZH2 Induces Proliferation and Progression in Prostate Cancer.FOXM1 依赖性转录调控 EZH2 诱导前列腺癌的增殖和进展。
Anticancer Agents Med Chem. 2021;21(14):1835-1841. doi: 10.2174/1871520620666200731161810.
2
Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics.泛癌分析 CDK12 改变鉴定出具有独特基因组和临床特征的前列腺癌亚群。
Eur Urol. 2020 Nov;78(5):671-679. doi: 10.1016/j.eururo.2020.03.024. Epub 2020 Apr 19.
3
Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer.
三阴性乳腺癌对紫杉醇的反应模拟了干扰素反应，揭示了与细胞周期相关的耐药机制。
bioRxiv. 2024 Jun 6:2024.06.04.596911. doi: 10.1101/2024.06.04.596911.
转移性去势敏感型前列腺癌中的致癌基因组改变、临床表型和结果
Clin Cancer Res. 2020 Jul 1;26(13):3230-3238. doi: 10.1158/1078-0432.CCR-20-0168. Epub 2020 Mar 27.
4
The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness.ETS 转录因子 ETV5 是神经母细胞瘤中激活的 ALK 的靶标，有助于增加肿瘤的侵袭性。
Sci Rep. 2020 Jan 14;10(1):218. doi: 10.1038/s41598-019-57076-5.
5
Assessing the Advantages, Limitations and Potential of Human Primary Prostate Epithelial Cells as a Pre-clinical Model for Prostate Cancer Research.评估人原发性前列腺上皮细胞作为前列腺癌研究临床前模型的优势、局限性和潜力。
Adv Exp Med Biol. 2019;1164:109-118. doi: 10.1007/978-3-030-22254-3_9.
6
Hyperpolarized MRI of Human Prostate Cancer Reveals Increased Lactate with Tumor Grade Driven by Monocarboxylate Transporter 1.人前列腺癌的超极化 MRI 显示乳酸水平升高，其与肿瘤分级相关，由单羧酸转运蛋白 1 驱动。
Cell Metab. 2020 Jan 7;31(1):105-114.e3. doi: 10.1016/j.cmet.2019.08.024. Epub 2019 Sep 26.
7
Genomic correlates of clinical outcome in advanced prostate cancer.晚期前列腺癌的临床结局的基因组相关性。
Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436. doi: 10.1073/pnas.1902651116. Epub 2019 May 6.
8
ETS transcription factors as emerging drug targets in cancer.ETS 转录因子作为癌症治疗的新兴药物靶点
Med Res Rev. 2020 Jan;40(1):413-430. doi: 10.1002/med.21575. Epub 2019 Mar 29.
9
Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.早期前列腺癌的分子进化确定了分子风险标志物和临床轨迹。
Cancer Cell. 2018 Dec 10;34(6):996-1011.e8. doi: 10.1016/j.ccell.2018.10.016.
10
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.起源细胞模式主导了 33 种癌症类型的 10000 个肿瘤的分子分类。
Cell. 2018 Apr 5;173(2):291-304.e6. doi: 10.1016/j.cell.2018.03.022.